#Digital Neuro Biomarkers Market Size

[luckydige45]

According to Nova One Advisor, the global digital neuro biomarkers market size was valued at USD 619.70 million in 2023. The market is anticipated to grow from USD 777.10 Million in 2024 to USD 5,958.77 million by 2033, exhibiting a CAGR of 25.4% during the forecast period.

[waquasuniverse]

Digital Neuro Biomarkers Market To Reach $2.82Bn By 2030

The global digital neuro biomarkers market size is anticipated to reach USD 2.82 billion by 2030 and is projected to grow at a CAGR 25.3% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is witnessing significant growth owing to various factors such as increased prevalence of neurological disorders, rising geriatric population globally, advances in technology,…

[tamanna31]

Clinical Decision Support Systems Market by Regions, Type & Applications During 2024-2030

Clinical Decision Support Systems Industry Overview 

The global clinical decision support systems market size was estimated at USD 5.30 billion in 2023 and is projected to grow at a CAGR of 10.79% from 2024 to 2030. Clinical decision support systems (CDSSs) have experienced significant advancement in recent decades, providing clinicians with vital tools to make informed decisions in patient care. These systems have emerged as a promising means to improve patient outcomes and reduce overall healthcare costs. 

Gather more insights about the market drivers, restrains and growth of the Clinical Decision Support Systems Market 

AI and ML technologies are transforming the CDSS market, offering advanced functionalities such as predictive analytics, pattern recognition, and tailored recommendations. AI-driven CDSSs can analyze extensive datasets, detect patterns, anticipate outcomes, and suggest optimal treatment strategies. Researchers are integrating AI with CDSS, as demonstrated by the University of Texas at Austin’s Dell Medical School researchers who developed an AI-based CDSS to aid clinicians in discussing nutrition and making decisions with patients about diet improvements in December 2022. 

The adoption of personalized medicine is increasing, with CDSSs playing a crucial role. These systems analyze patient data, including genetic profiles and medical histories, to customize treatment plans for individuals. By providing tailored recommendations, CDSSs enhance treatment effectiveness and reduce the risk of adverse reactions, driving market growth. 

Governments worldwide are implementing regulations and incentives to promote CDSS and other healthcare IT solutions. These regulations focus on enhancing patient safety, interoperability, and care quality, prompting healthcare organizations to invest in CDSS to comply with regulatory requirements and qualify for incentives. 

The COVID-19 pandemic has also positively impacted the market growth, leading to increased adoption of CDSS. CDSSs have been instrumental in supporting patient resources and services, as demonstrated by their role in real-time clinical diagnosis of COVID-19 and patient triage. Various countries offering online services have further fueled market growth. Market players have introduced CDSSs for managing COVID-19 data and insights. For instance, in May 2022, Epocrates launched an innovative tool for long COVID-19, integrating the latest updates to expand the collection of clinical decision support guidelines. Consequently, the increased adoption and introduction of clinical decision support systems have propelled market growth during the pandemic. 

Browse through Grand View Research's Healthcare IT Industry Research Reports.

The global biohacking market size was valued at USD 20.94 billion in 2023 and is projected to grow at a CAGR of 18.6% from 2024 to 2030. 

The global digital neuro biomarkers market size was estimated at USD 593.1 million in 2023 and is projected to grow at a CAGR of 25.3% from 2024 to 2030.  

Clinical Decision Support Systems Market Segmentation 

Grand View Research has segmented the global clinical decision support systems market report based on product, application, delivery mode, component, and region: 

Clinical Decision Support Systems Product Outlook (Revenue, USD Million, 2018 - 2030)

Standalone CDSS

Integrated CPOE with CDSS

Integrated EHR with CDSS

Integrated CDSS with CPOE & EHR 

Clinical Decision Support Systems Application Outlook (Revenue, USD Million, 2018 - 2030)

Drug-drug interactions

Drug allergy alerts

Clinical reminders

Clinical guidelines

Drug dosing support

Others 

Clinical Decision Support Systems Delivery Mode Outlook (Revenue, USD Million, 2018 - 2030)

Web-based Systems

Cloud-based Systems

On-premise Systems 

Clinical Decision Support Systems Component Outlook (Revenue, USD Million, 2018 - 2030)

Hardware

Software

Services 

Clinical Decision Support Systems Regional Outlook (Revenue, USD Million, 2018 - 2030)

North America

US

Canada

Europe

Germany

UK

Italy

Spain

France

Sweden

Denmark

Norway

Asia Pacific

China

India

Japan

Thailand

South Korea

Australia

Latin America

Brazil

Mexico

Argentina

Middle East & Africa

South Africa

Saudi Arabia

UAE

Kuwait 

Order a free sample PDF of the Clinical Decision Support Systems Market Intelligence Study, published by Grand View Research. 

Key Companies profiled:

McKesson Corporation

Oracle (Cerner Corporation)

Siemens Healthineers GmbH

Allscripts Healthcare, LLC

athenahealth, Inc.

NextGen Healthcare Inc.

Koninklijke Philips N.V.

IBM

Agfa-Gevaert Group (IG Farben)

Wolters Kluwer N.V. 

Recent Developments

In October 2023, Wolters Kluwer Health launched AI Labs, a collective resource to integrate generative AI with UpToDate, its CDS solution, enabling medical professionals to make better-informed decisions

In August 2023, GE HealthCare launched CardioVisio for Atrial Fibrillation, a patient-centric, digital CDS tool to allow precision care

In February 2023, EBSCO Information Services launched new features in DynaMedex Mobile App to improve clinical decision support. These enhancements improve the mobile experience for users by enabling clinicians to deliver evidence-based patient care efficiently

Moreover, in May 2020, DHIndia announced a partnership with EHRC@IIITB & Healthelife to develop a CDSS for the screening of COVID-19. The partnership also included the formation of a minimal triage application for front-line doctors

In March 2020, IBM Watson Health partnered with EBSCO Information Services to enhance CDSS and operations for healthcare systems and providers 

[poonamcmi]

Neurodiagnostics Market Estimated to Witness High Growth Owing to Growing Geriatric Population

​The neurodiagnostics market plays a crucial role in neurological disease diagnosis and treatment monitoring. Neurological disorders such as epilepsy, Alzheimer's disease, Multiple Sclerosis, Parkinson's disease, and other neurological conditions are becoming increasingly prevalent. Neurodiagnostics help detect neurological abnormalities through neurological imaging such as MRI, EEG, and diagnostic tests. The growing geriatric population is more susceptible to neurodegenerative diseases, driving the need for neurodiagnostics.

The Global Neurodiagnostics Market is estimated to be valued at US$ 8.66 Bn in 2024 and is expected to exhibit a CAGR of 8.1% over the forecast period 2024 To 2031.

Key Takeaways Key players operating in the neurodiagnostics are Koninklijke Philips N.V, Siemens Healthcare GmbH, F. Hoffmann-La Roche Ltd, FUJIFILM Holdings Corporation, Bio-Rad Laboratories Inc., Advanced Brain Monitoring, Inc., Nihon Kohden Corporation, Mitsar Co. LTD., EMS Biomedical, Mennen Medical, Natus Medical Incorporated, Medicaid Systems, Fujirebio, FONAR Corp, ANT Neuro, NEUROLITE AG, and Atlantic Health System.

The Neurodiagnostics Market Trends  include increasing investments in R&D for biomarker-based disease diagnosis and neuroimaging. The global expansion of key players through mergers and acquisitions will further aid market growth.

The growing geriatric population is more susceptible to neurodegenerative diseases, driving the need for neurodiagnostics. Furthermore, increasing investments in R&D by key players for developing advanced diagnostic systems will boost the neurodiagnostics market over the forecast period.

Market drivers The growing geriatric population is the major driver propelling the Neurodiagnostics Market Size And Trends As per the United Nations, people aged over 60 years are projected to outnumber children under 10 years by 2050. Elderly people are more vulnerable to neurological disorders like Alzheimer's and Parkinson's disease. This will augment the demand for neurodiagnostics for early disease diagnosis and treatment monitoring. Increasing awareness about brain health and availability of reimbursement policies for neurodiagnostic tests will also boost market revenues significantly over the forecast period.

PEST Analysis Political: Regulations related to medical devices and neurological disorder treatments have an impact. Reimbursement policies by governments and insurance agencies also affect market growth. Economic: The growing insurance coverage levels and disposable incomes have boosted healthcare spending including on neurodiagnostics. Higher investments in clinical trials and R&D remain crucial. Social: Rising prevalence of neurological disorders like Alzheimers, Parkinsons, epilepsy, and stroke is a key driver. Growing awareness encourages early diagnosis through imaging techniques. Technological: Advancements in imaging modalities like MRI, CT, PET, EEG, and newer technologies like digital EEG and MEG expands diagnosis capabilities. Portable and wearable devices improve accessibility.

Geographical Regions with High Market Concentration North America accounts for the largest share in the neurodiagnostics market in terms of value, owing to the presence of major players, high healthcare expenditure, and rising neurological disorders. The United States holds a significant share in the regional market.

Fastest Growing Regional Market The Asia Pacific region is expected to witness the highest growth in the neurodiagnostics market during the forecast period. This is attributed to factors such as growing healthcare expenditure, increasing healthcare infrastructure development, and rising geriatric population in the region suffering from neurological conditions. Rapidly developing countries like China and India with huge patient pools offer high growth potential. Get More Insights On, Neurodiagnostics Market About Author: Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163)

[marketresearchlatestreports]

Brain Computer Interface Market Analysis, Competitor Tracking, Opportunities And Strategies To Boost Growth

The global brain computer interface market will observe a growth at 14.0% CAGR, reaching a projected valuation of USD 5.46bn by 2028, while it valued at USD 1.48bn in 2021.

The Healthcare sector is ever growing and with the digitalization and onset of covid 19 pandemic, the demand for telehealth services is surging, which would expand the brain computer interface market during the forecast period.

ResearchMoz in its report elucidates the global brain computer interface market in-depth, which includes the size, growth drivers, opportunities, restraints, challenges, regional growth along with competitive edge.

Healthcare Sector Bolsters the Demand

The applications of brain-computer interfaces such as controlling prosthetic limbs, assisting people with disabilities, and treating conditions like epilepsy and Parkinson’s disease will boost the demand in the coming years. Further, the high applicability of this device in treatments such as neurological diseases and sleep disorders will bolster the growth opportunities for the brain computer interface market over the forecast period.

Get FREE PDF Sample Copy of this Report (Including Full TOC, List of Tables & Figures, Chart)@ https://www.researchmoz.us/request-free-sample/?reportid=1451

Competitive Landscape

The detailed report on many strategies undertaken by the major players is available with ResearchMoz, which would help new entrants to make informed and smart decision to thrive in the market.

The key players are investing heavily on research and development and product innovation to capture the untapped markets and position themselves in the global brain computer interface market.

The current key players of the brain computer interface market are –

Brain Products GmbH

Integra Lifesciences Corporation

Advanced Brain Monitoring, Inc.

Compumedics Neuroscan

NIRx Medical Technologies, LLC

OpenBCI

CGX, A Cognionics Company

Natus Medical Incorporated

tec medical engineering GmbH

Interaxon, Inc.

ANT Neuro

Medtronic

EMOTIV

NeuroSky

ANT Neuro

Key Takeaways

ResearchMoz analyses the brain-computer interface market thoroughly and shares a comprehensive report that includes all the aspects of the market such as size, opportunities, threats, drivers, etc. The report is based on factual information and projections, which will enable stakeholders to stay updated to succeed in this area.

Some of the key takeaways from the report are as follows-

The global brain-computer interface market is projected to grow at a CAGR of 14.0% between 2021 to 2028

An increasing number of initiatives undertaken by governments and private organizations to promote the use of BCIs in various medical applications such as neurodegenerative diseases, epilepsy, paralysis, and traumatic brain injury.

The increasing adoption of BCI-enabled devices for gaming and entertainment applications is driving the growth of this market in the coming years.

The rising number of research and development activities are expected to drive the growth of the BCI market during the forecast period.

Share Your Requirements & Get Customized Reports @ https://www.researchmoz.us/enquiry-before-buying/?reportid=1451

Product Outlook (Revenue, USD Billion)

Invasive BCI

Non-invasive BCI

Partially Invasive BCI

Application Outlook (Revenue, USD Billion)

Smart Home Control

Communication & Control

Entertainment & Gaming

Disabilities Restoration

Brain Function Repair

Healthcare

End-use Outlook (Revenue, USD Billion)

Military

Medical

Others

Download Report PDF: Brain Computer Interface Market

More Trending Reports by ResearchMoz –

Cataract Surgery Devices Market - https://researchmozblog.wordpress.com/2022/06/16/cataract-surgery-devices-market-to-garner-bursting-revenues-by-2030/

Cardiac Prosthetic Devices Market - https://researchmozblog.wordpress.com/2022/06/16/cardiac-prosthetic-devices-is-set-to-experience-innovative-growth-by-2026/

Cardiac Biomarkers Market - https://researchmozblog.wordpress.com/2022/06/16/cardiac-biomarkers-market-may-double-its-revenue-size-in-coming-decade/

Blood Glucose Monitoring Devices Market - https://researchmozblog.wordpress.com/2022/06/16/blood-glucose-monitoring-devices-market-rewriting-long-term-growth-story/

Cardiac Arrhythmia Monitoring Devices Market -

https://researchmozblog.wordpress.com/2022/06/16/cardiac-arrhythmia-monitoring-devices-market-growing-opportunity-and-competitive-landscape/

About ResearchMoz

ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfil all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organisations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

For More Information Kindly Contact:

ResearchMoz Abhishek Budholiya Tel: +1-518-621-2074 USA-Canada Toll Free: 866-997-4948 Email: sales@researchmoz.us Follow us on LinkedIn: https://www.linkedin.com/company/researchmoz Follow us on Twitter: https://twitter.com/researchmoz Media Release: https://www.researchmoz.us/pressrelease

[smitadeshmukh123]

Neurodiagnostics Market 2024: Analysis, Growth, Drivers, Vendors Landscape, Shares, Size, Trends, Challenges, Segmentation with Forecast

Neurodiagnostics or neurodiagnostic tests monitor and record electrical activities of patient’s brain, spinal cord and peripheral nerves. The US National Institute of Mental Health (NIMH) estimates that approximately one in four individual suffers from diagnosable mental disorder each year. One in seventeen which is approximately 13.6 million people live with serious mental illnesses such as schizophrenia, major depression or bipolar disorder. Serious mental illness costs the United States approximately USD 193.2 billion losses each year. Among other neural disorders, mood disorders such as depression are one of the most common causes of hospitalization among youth and adults in the U.S. aged between 18 years to 44 years. According to a report by the Alzheimer’s Association approximately 5.1 million people in the United States suffers from Alzheimer’s disease in 2012 and by 2020, the statistical data is likely to touch 16 million bar with one new case appearing in every 33 seconds. Autism and Autism Spectrum Disorders, according to an analysis by the Centers for Disease Control is estimated to affect 1 in every 88 children in the U.S. Similar studies conducted in other countries, for instance the UK National Health Service estimates the prevalence of Autism Spectrum disorders among adults in England is approximately one percent in 2012. The economic cost associated with Autism in the U.S. and U.K. is estimated to be approximately USD 35 billion and USD 45 billion (£27 billion) respectively each year.

Obtain Report Details: http://www.transparencymarketresearch.com/neurodiagnostics-market.html

Prevalence of other prominent diseases such as multiple sclerosis, narcolepsy and sleep disorders and strokes among others accounted for 400,000, 14.3 million and 4,700,000 individuals respectively between 2001 and 2014. With such a growing population of neurological disorders across the globe the market for neurodiagnostics will positively emerge out as a prospecting and lucrative market in coming years. Diagnosis of these neurological disorders is rapidly changing as new tools now a day developed are coming up with the sole intention of rendering personalized assessment and treatment. In general the market for neurodiagnostics can be segmented on the basis of nuroimaging techniques, in-vitro diagnostic techniques and disease type. The market for neuroimaging techniques can be further sub-segmented into electro-encephalography, nuclear medicine imaging (pet), magneto-encephalography, and computed tomography among others. Whereas, market for in-vitro diagnostic include protein biomarker assay and genetic testing and pharmacogenomics among others.

The commonly occurring disease type encompasses attention disorder, Alzheimer's, anxiety disorder, schizophrenia, depression, epilepsy, Parkinson's disease, sensory disorders, and sleep disorders among others. Major drivers for the neurodiagnostics market comprises advances in diagnostic equipments, developments in biomarker assay techniques and increasing use of imaging techniques in drug development. Growing trend of cloud computing based EEG devices which can store all the diagnosis report, medication schedules and sharing of real time analysis with patients as well as other physicians is likely to uplift the neurodiagnostics market in coming years. The lack of regular diagnosis and mental health check up not in developing and emerging economies but even in developed parts of the world is one of the prominent and major restraints to the neurodiagnostics market. There are still millions of people who are yet undiagnosed and a large chunk of the affected population are carrying them for more than 5 years.

Fill the form for an exclusive sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=10247

Some of the prominent players in the neurological disorders include Neuro Diagnostic Devices, Inc., Lifelines Neurodiagnostics Systems Inc., Zynex NeuroDiagnostics, Digital NeuroDiagnostics, LLC, Ridge Diagnostics among others.

[tamanna31]

Clinical Trials 2024 Industry Size, Demands, Growth and Top Key Players Analysis Report

Clinical Trials Industry Overview

The global clinical trials market size was valued at USD 80.7 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 6.49% from 2024 to 2030. 

The market growth spiked in 2020 owing to the COVID-19 pandemic. This growth pattern was witnessed by both virtual clinical trials and traditional ones. Several companies invested heavily in novel drug development to minimize COVID-19 patient burden. One such example being, in 2020, Synairgen plc and Parexel collaborated on a Phase III study of Interferon-beta (IFN-beta) treatment for COVID-19. Furthermore, rapid technological evolution, rising prevalence of chronic diseases, globalization of clinical trials, penetration of personalized medicine and a rise in demand for CROs for conducting research activities is expected to positively impact the market growth.

Gather more insights about the market drivers, restrains and growth of theClinical Trials Market

In addition, the COVID-19 pandemic led to changing the ways of conducting upcoming or ongoing clinical trials. Regulatory agencies including the U.S. FDA, the European Medicines Agency (EMA), the National Institutes of Health (NIH), and China’s National Medical Products Administration among several others issued various guidelines for conducting trials during the pandemic to support the implementation of decentralized clinical trials and virtual services. The current scenario for research and development activities across the globe and the need for several new treatment options have also led to the adoption of fast-track clinical trials. Thus, aforementioned factors are estimated to offer new avenues to the clinical trials market growth.

Favorable government support and initiatives is another aspect boosting the market growth potential. For instance, the WHO launched Solidarity, an international clinical trial to determine effective treatment against COVID-19. [PS2]  It includes comparing four treatment options against the standard of care to evaluate their effectiveness against the coronavirus. In May 2020, the WHO also announced an international alliance for simultaneously developing multiple candidate vaccines to prevent the spread of the coronavirus disease, calling this effort the Solidarity trial for vaccines.

Furthermore, the use of CRO services helps manufacturers/sponsors pay complete attention to the production capacity and enhance their in-house processes. The availability of the vast array of services from drug discovery to post marketing surveillance has further simplified processes for mid-size & small-scale pharmaceutical and biotechnological organizations by providing them the option to outsource research and development activities to reduce infrastructure investment. For instance, in November 2023, Syneos Health signed an agreement with GoBroad Healthcare Group. This collaborative initiative extended the company’s clinical trial capabilities into a more extensive array of therapeutic areas in China.

Browse through Grand View Research's Healthcare IT Industry Research Reports.

The global digital neuro biomarkers market size was estimated at USD 593.1 million in 2023 and is projected to grow at a CAGR of 25.3% from 2024 to 2030.

The global healthcare digital experience platform market size was valued at USD 1.26 billion in 2023 and is forecasted to grow at a CAGR of 12.5% from 2024 to 2030.

Clinical Trials Market Segmentation

Grand View Research has segmented the global clinical trials market based on phase, study design, indication, sponsor, indication by study design, and region:

Clinical Trials Phase Outlook (Revenue, USD Billion, 2018 - 2030)

Phase I

Phase II

Phase III

Phase IV

Clinical Trials Study Design Outlook (Revenue, USD Billion, 2018 - 2030)

Interventional

Observational

Expanded Access

Clinical Trials Indication by Study Design Outlook (Revenue, USD Billion, 2018 - 2030)

Autoimmune/Inflammation

Rheumatoid Arthritis

Multiple Sclerosis

Osteoarthritis

Irritable Bowel Syndrome (IBS)

Others

Pain Management

Chronic Pain

Acute Pain

Oncology

Blood Cancer

Solid Tumors

Other

CNS Condition

Epilepsy

Parkinson's Disease (PD)

Huntington's Disease

Stroke

Traumatic Brain Injury (TBI)

Amyotrophic Lateral Sclerosis (ALS)

Muscle Regeneration

Others

Diabetes

Obesity

Cardiovascular

Others

Clinical Trials Indication Outlook (Revenue, USD Billion, 2018 - 2030)

Autoimmune/Inflammation

Interventional

Observational

Expanded Access

Pain Management

Interventional

Observational

Expanded Access

Oncology

Interventional

Observational

Expanded Access

CNS Condition

Interventional

Observational

Expanded Access

Diabetes

Interventional

Observational

Expanded Access

Obesity

Interventional

Observational

Expanded Access

Cardiovascular

Interventional

Observational

Expanded Access

Others

Interventional

Observational

Expanded Access

Clinical Trials Sponsor Outlook (Revenue, USD Billion, 2018 - 2030)

Pharmaceutical & Biopharmaceutical Companies

Medical Device Companies

Others

Clinical Trials Service Type Outlook (Revenue, USD Billion, 2018 - 2030)

Protocol Designing

Site Identification

Patient Recruitment

Laboratory Services

Bioanalytical Testing Services

Clinical Trial Data Management Services

Others

Clinical Trials Regional Outlook (Revenue, USD Billion, 2018 - 2030)

North America

US

Canada

Europe

UK

Germany

France

Spain

Italy

Asia Pacific

India

Japan

China

Australia

South Korea

Latin America

Brazil

Mexico

Argentina

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

Key Companies profiled:

IQVIA

PAREXEL International Corporation

Pharmaceutical Product Development, LLC

Charles River Laboratory

ICON Plc

PRA Health Sciences

Syneos Health

Eli Lilly and Company

Novo Nordisk A/S

Pfizer

Clinipace

Recent Developments

In August 2023, Parexel & Partex entered a strategic partnership aimed at utilizing Artificial Intelligence (AI)-driven solutions to expedite the process of drug discovery and development for biopharmaceutical clients globally. The collaboration aimed to reduce risks associated with the assets in their respective portfolios.

In August 2023, Novo Nordisk announced to acquire Inversago Pharma. This acquisition was part of Novo Nordisk's strategic efforts to develop new therapies targeting individuals with obesity, diabetes, and other significant metabolic diseases

Order a free sample PDF of the Clinical Trials Market Intelligence Study, published by Grand View Research.

[poonamcmi]

Neurodiagnostics Market Estimated to Witness High Growth Owing to Growing Geriatric Population

The neurodiagnostics market plays a crucial role in neurological disease diagnosis and treatment monitoring. Neurological disorders such as epilepsy, Alzheimer's disease, Multiple Sclerosis, Parkinson's disease, and other neurological conditions are becoming increasingly prevalent. Neurodiagnostics help detect neurological abnormalities through neurological imaging such as MRI, EEG, and diagnostic tests. The growing geriatric population is more susceptible to neurodegenerative diseases, driving the need for neurodiagnostics.

The Global Neurodiagnostics Market is estimated to be valued at US$ 8.66 Bn in 2024 and is expected to exhibit a CAGR of 8.1% over the forecast period 2024 To 2031.

Key Takeaways

Key players operating in the neurodiagnostics are Koninklijke Philips N.V, Siemens Healthcare GmbH, F. Hoffmann-La Roche Ltd, FUJIFILM Holdings Corporation, Bio-Rad Laboratories Inc., Advanced Brain Monitoring, Inc., Nihon Kohden Corporation, Mitsar Co. LTD., EMS Biomedical, Mennen Medical, Natus Medical Incorporated, Medicaid Systems, Fujirebio, FONAR Corp, ANT Neuro, NEUROLITE AG, and Atlantic Health System.

The key opportunities in the Neurodiagnostics Market Demand include increasing investments in R&D for biomarker-based disease diagnosis and neuroimaging. The global expansion of key players through mergers and acquisitions will further aid market growth.

The growing geriatric population is more susceptible to neurodegenerative diseases, driving the need for neurodiagnostics. Furthermore, increasing investments in R&D by key players for developing advanced diagnostic systems will boost the neurodiagnostics market over the forecast period.

Market drivers

The growing geriatric population is the major driver propelling the Neurodiagnostics Market Size And Trends As per the United Nations, people aged over 60 years are projected to outnumber children under 10 years by 2050. Elderly people are more vulnerable to neurological disorders like Alzheimer's and Parkinson's disease. This will augment the demand for neurodiagnostics for early disease diagnosis and treatment monitoring. Increasing awareness about brain health and availability of reimbursement policies for neurodiagnostic tests will also boost market revenues significantly over the forecast period.

PEST Analysis

Political: Regulations related to medical devices and neurological disorder treatments have an impact. Reimbursement policies by governments and insurance agencies also affect market growth. Economic: The growing insurance coverage levels and disposable incomes have boosted healthcare spending including on neurodiagnostics. Higher investments in clinical trials and R&D remain crucial. Social: Rising prevalence of neurological disorders like Alzheimers, Parkinsons, epilepsy, and stroke is a key driver. Growing awareness encourages early diagnosis through imaging techniques. Technological: Advancements in imaging modalities like MRI, CT, PET, EEG, and newer technologies like digital EEG and MEG expands diagnosis capabilities. Portable and wearable devices improve accessibility.

Geographical Regions with High Market Concentration North America accounts for the largest share in the neurodiagnostics market in terms of value, owing to the presence of major players, high healthcare expenditure, and rising neurological disorders. The United States holds a significant share in the regional market.

Fastest Growing Regional Market

The Asia Pacific region is expected to witness the highest growth in the neurodiagnostics market during the forecast period. This is attributed to factors such as growing healthcare expenditure, increasing healthcare infrastructure development, and rising geriatric population in the region suffering from neurological conditions. Rapidly developing countries like China and India with huge patient pools offer high growth potential. Get More Insights On, Neurodiagnostics Market About Author: Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163)